Elsevier

Bone

Volume 55, Issue 2, August 2013, Pages 384-390
Bone

Original Full Length Article
Deferoxamine expedites consolidation during mandibular distraction osteogenesis

https://doi.org/10.1016/j.bone.2013.04.005Get rights and content

Highlights

  • We examine accelerated consolidation in a murine model of mandibular distraction osteogenesis at abridged time-points.

  • We report quantifiable radiomorphometrics of bone quality and metrics of biomechanical strength.

  • We demonstrate the degree of acceleration of consolidation during distraction, with the utility of angiogenic deferoxamine therapy.

Abstract

Background

A limitation of mandibular distraction osteogenesis (DO) is the length of time required for consolidation. This drawback subjects patients to possible pin-site infections, as well as a prolonged return to activities of normal daily living. Developing innovative techniques to abridge consolidation periods could be immensely effective in preventing these problematic morbidities. Deferoxamine (DFO) is an angiogenic activator that triggers the HIF-1α pathway through localized iron depletion. We previously established the effectiveness of DFO in enhancing regenerate vascularity at a full consolidation period (28 days) in a murine mandibular DO model. To investigate whether this augmentation in vascularity would function to accelerate consolidation, we progressively shortened consolidation periods prior to μCT imaging and biomechanical testing (BMT).

Materials and methods

Three time points (14 d, 21 d and 28 d) were selected and six groups of Sprague–Dawley rats (n = 60) were equally divided into control (C) and experimental (E) groups for each time period. Each group underwent external fixator placement, mandibular osteotomy, and a 5.1 mm distraction. During distraction, the experimental groups were treated with DFO injections into the regenerate gap. After consolidation, mandibles were imaged and tension tested to failure. ANOVA was conducted between groups, and p < 0.05 was considered statistically significant.

Results

At 14 days of consolidation the experimental group demonstrated significant increases in bone volume fraction (BVF), bone mineral density (BMD) and ultimate load (UL) in comparison to non-treated controls. The benefit of treatment was further substantiated by a striking 100% increase in the number of bony unions at this early time-period (C:4/10 vs. E:8/10). Furthermore, metrics of BVF, BMD, Yield and UL at 14 days with treatment demonstrated comparable metrics to those of the fully consolidated 28 d control group.

Conclusion

Based on these findings, we contend that augmentation of vascular density through localized DFO injection delivers an efficient means for accelerating bone regeneration without significantly impacting bone quality or strength.

Introduction

Mandibular distraction osteogenesis (DO) has emerged as an efficacious surgical technique for the treatment of congenital retrognathia, micrognathia and mandibular hypoplasia. Increasing surgeon experience and device innovation has allowed for the expansion of this attractive technique throughout the craniofacial skeleton to allow for the correction of maxillary hypoplasia, midface hypoplasia and craniosynostosis [1], [2], [3], [4]. Despite these clinical advancements, the length of time required for bone consolidation continues to be a significant limitation to the widespread use of this procedure [5].

In contrast to fracture healing in which bone takes six to eight weeks to heal, DO requires device manipulation during lengthening and a subsequent consolidation period that is proportional to the amount of bone lengthening. This consolidation period ranges from approximately two to six months depending on the desired length and anatomic location of distraction [3], [6].

Numerous factors play a role in the success of DO, with blood flow as paramount to the formation of a healthy union. The importance of sufficient blood flow to the fractured ends during consolidation is related to osteoblast survival [7], [8], [9]. Osteoblast survival, in turn, relies on the close proximity of these cells to nutrient vessels (< 100 μm) [10], [11]. Studies of non-unions demonstrate ischemic, fibrous tissue; whereas healthy unions often demonstrate high levels of neovascularization and active osteogenesis [12]. The dense vascular network in the craniofacial skeleton allows for a high success rate of DO; however, improved angiogenesis would reasonably lead to faster consolidation. Improving vascularity would not only enhance osteogenesis through improved blood flow to osteoblasts, but vascular tissues themselves also secrete osteogenic cytokines such as BMP-2 and vasculogenic cytokines such as VEGFA, which have also been shown to enhance osteogenesis [13].

Other novel treatment methods of distraction optimization have been reported; however, considerable regulatory hurdles have prevented translation of these methods to the clinical arena [14], [15], [16], [17]. A therapeutic paradigm focused on the optimization of vascularity with an established, FDA approved therapy may be a strategy for distraction optimization with real translational potential.

Recent tissue engineering strategies have shed light on the use of angiogenesis and vascular augmentation as mechanisms to enhance bone regeneration in long bone murine models. Investigators have utilized deferoxamine, an iron chelator with angiogenic properties, to trigger angiogenesis and report quantifiable enhancements in vascularity at 14 days and bone quality at 28 days—a widely accepted normal time-point for expected full consolidation [9], [18]. Deferoxamine exerts its angiogenic function through the stimulation of the HIF-1 α pathway. Iron is a co-factor in a reaction that leads to the degradation of HIF-1α. In the absence of iron, the production of HIF-1 α becomes constitutive resulting in an accumulation of the factor in the nucleus. HIF-1 α then dimerizes and begins a transcriptional cascade of events leading to the production of VEGF, as well as other downstream angiogenic factors. Deferoxamine simply removes iron from this equation, thereby triggering angiogenesis and subsequently, new blood vessel formation [18], [19], [20].

We previously reported on the ability of deferoxamine to successfully augment vascularity and bone cellularity even beyond that of the normal regenerative response in our rat model of mandibular DO at a full 28 d consolidation period. Our results demonstrated a significant 40% increase in vessel number and a 45% increase in osteocytes within the regenerate site [21], [22].

In order to expand on our findings, we aim to investigate the therapeutic potential of deferoxamine to substantially shorten consolidation periods. Here we examine its utility in our model at three consecutive time-points (14 d, 21 d and 28 d). We posit that the addition of deferoxamine will allow for successful consolidation at substantially shortened time-points (14 and 21 days) without compromising regenerate quality or mechanical strength when compared to a normal, fully consolidated regenerate (28 days).

Section snippets

Experimental design

Twelve-week-old male Sprague Dawley rats weighing approximately 400 g were paired in cages and maintained in a pathogen-free environment on a 12-hour light/dark schedule. Six groups of animals (n = 60) were equally divided into control (C) and experimental (E) groups for each time-period (n = 10 per group). Three time-points of consolidation were chosen (14 d, 21 d and 28 d). The 28 d time-point was selected as a full, standard consolidation period based on what is widely accepted in the literature and

μCT results

Radiomorphometrics collected through μCT imaging revealed the clear effects of therapy at each time point (Fig. 2, Fig. 3a–c; Table 1, Table 2).

In comparison to the standard 28 d fully consolidated control (28 d C), radiomorphometric analyses of the non-treated group at 14 days (14d C) demonstrated an expected significant disparity in BVF and BMD (both were 77% of 28 d C). This difference was not apparent with deferoxamine therapy, indicating a benefit of treatment at the earliest time-point (14 d E

Discussion

In the present study we investigated the therapeutic potential of deferoxamine to accelerate regenerate consolidation after mandibular DO. While other methods to accelerate consolidation have been attempted, we specifically aimed to optimize an ongoing and well-established phenomenon occurring during distraction. Angiogenesis and vascular augmentation in response to the mechanical stretching of a callus are critical mechanisms integral to the successful regeneration of bone [10], [29], [30],

Disclosure/financial support

All authors state that they have no conflicts of interest.

Acknowledgments

The authors would like to thank Charles Roehm for fabrication of fixator devices.

References (32)

  • K. Andersen et al.

    A retrospective study of cleft lip and palate patients satisfaction after maxillary distraction or traditional advancement of the maxilla

    J. Oral Maxillofac. Surg.

    (2012)
  • Z.S. Ai-Aql et al.

    Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis

    J. Dent. Res.

    (2008)
  • J. Glowacki

    Angiogenesis in fracture repair

    Clin. Orthop. Relat. Res.

    (1998)
  • A. Donneys et al.

    Bone regeneration in distraction osteogenesis demonstrates significantly increased vascularity in comparison to fracture repair in the mandible

    J. Craniofac. Surg.

    (2012)
  • J. Aronson

    Temporal and spatial increases in blood flow during distraction osteogenesis

    Clin. Orthop. Relat. Res.

    (1994)
  • T.D. Fang et al.

    Angiogenesis is required for successful bone induction during distraction osteogenesis

    J. Bone Miner. Res.

    (2005)
  • Cited by (43)

    • MIF does only marginally enhance the pro-regenerative capacities of DFO in a mouse-osteotomy-model of compromised bone healing conditions

      2022, Bone
      Citation Excerpt :

      We did not observe an add-on effect by MIF. The observation the pro-regenerative capabilities of DFO are in line with several previous reports on DFO administered in rat- or mouse-osteotomy models of Ossa irregularia (mandibula or zygomatic arch) and long bones (femur or tibia) [12,20,43,44]. All studies showed a strong positive effect of DFO on bone and vessel formation although the application routes and concentrations differed.

    • Siderophores for medical applications: Imaging, sensors, and therapeutics

      2021, International Journal of Pharmaceutics
      Citation Excerpt :

      Afterward, they found that transdermal DFO can similarly prevent pressure ulcers and normalize aged wound healing (Bonham et al., 2018). The pro-angiogenesis function of DFO was also utilized to expedite bone consolidation during mandibular Distraction Osteogenesis (DO) in a murine mandibular DO model (Donneys et al., 2013). Dihydroxybenzoic acids (DBHA), a siderophore from P. aeruginosa S1, can inhibit MMPs to accelerate wound healing owing to their metal-chelating property.

    • Histologic Improvements in Irradiated Bone Through Pharmaceutical Intervention in Mandibular Distraction Osteogenesis

      2018, Journal of Oral and Maxillofacial Surgery
      Citation Excerpt :

      The preservation of cellular abundance would therefore maintain the levels of angiogenic factors necessary for normal bone healing. The subsequent use of DFO treatment also may enhance the bone healing process by addressing the metabolic and vascular demands of bone regeneration through upregulation of the hypoxia-inducible factor 1-α pathway and vascular endothelial growth factor production.32,42,43 The potential synergy between AMF and DFO is further corroborated in this study by a significant increase in mature BV in the CT group in comparison with all other groups, including nonirradiated DO controls.

    View all citing articles on Scopus

    Funding was provided by the American Society of Maxillofacial Surgeons grant award to A Donneys for the proposal titled “The Effect of Deferoxamine on the Rate of Consolidation in Distraction Osteogenesis”. Further funding was provided by NIH T32-GM 008616 for A. Donneys and NIH RO1 CA 12587-01 for S. R. Buchman.

    View full text